Clinical Trial Update: A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tislelizumab with sitravatinib as maintenance therapy for extensive-stage small cell lung cancer (ES-SCLC).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• Sitravatinib (sitravatinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Lung Cancer, Small Cell | Phase 2 | Status: UNKNOWN